Loading...

Tamanoi Fuyuhiko

Title(s)Professor, Microbiology Immunology & Molecular Genetics
Phone310-825-7754
vCardDownload vCard
    Other Positions
    Title(s)Director, JCCC Signal Transduction and Therapeutics Program Area


    Collapse Research 
    Collapse Research Activities and Funding
    Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
    NIH/NCI R01CA133697Jan 1, 2010 - Jun 30, 2015
    Role: Principal Investigator
    FASEB Summer Conference, July 20-25, 2002
    NIH/NCI R13CA096588Jul 1, 2002 - Jun 30, 2003
    Role: Principal Investigator
    NEUROFIBROMATOSIS TYPE I GENE PRODUCT
    NIH/NINDS R01NS030054Sep 30, 1991 - Jul 31, 1996
    Role: Principal Investigator
    Activating mutants of mTOR
    NIH/NCI R01CA041996Jun 1, 1985 - Apr 30, 2015
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Tamanoi F. Recent excitements in the study of the CAM assay. Enzymes. 2019; 46:1-9. PMID: 31727271.
      View in: PubMed
    2. Matsumoto K, Saitoh H, Doan TLH, Shiro A, Nakai K, Komatsu A, Tsujimoto M, Yasuda R, Kawachi T, Tajima T, Tamanoi F. Destruction of tumor mass by gadolinium-loaded nanoparticles irradiated with monochromatic X-rays: Implications for the Auger therapy. Sci Rep. 2019 Sep 30; 9(1):13275. PMID: 31570738.
      View in: PubMed
    3. Komatsu A, Matsumoto K, Saito T, Muto M, Tamanoi F. Patient Derived Chicken Egg Tumor Model (PDcE Model): Current Status and Critical Issues. Cells. 2019 05 10; 8(5). PMID: 31083409.
      View in: PubMed
    4. Tamanoi F. Preface. Enzymes. 2019; 46:xiii. PMID: 31727280.
      View in: PubMed
    5. Matsumoto K, Le Hoang Doan T, Mai NXD, Nakai K, Komatsu A, Tamanoi F. Anticancer Drug Delivery Capability of Biodegradable PMO in the Chicken Egg Tumor Model. Enzymes. 2018; 44:103-116. PMID: 30360810.
      View in: PubMed
    6. Le Hoang Doan T, Mai NXD, Matsumoto K, Tamanoi F. Tumor Targeting and Tumor Growth Inhibition Capability of Mesoporous Silica Nanoparticles in Mouse Models. Enzymes. 2018; 44:61-82. PMID: 30360815.
      View in: PubMed
    7. Vallet-Regi M, Tamanoi F. Overview of Studies Regarding Mesoporous Silica Nanomaterials and Their Biomedical Application. Enzymes. 2018; 43:1-10. PMID: 30244802.
      View in: PubMed
    8. Vu BT, Shahin SA, Croissant J, Fatieiev Y, Matsumoto K, Le-Hoang Doan T, Yik T, Simargi S, Conteras A, Ratliff L, Jimenez CM, Raehm L, Khashab N, Durand JO, Glackin C, Tamanoi F. Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. Sci Rep. 2018 06 04; 8(1):8524. PMID: 29867159.
      View in: PubMed
    9. Omar H, Moosa B, Alamoudi K, Anjum DH, Emwas AH, El Tall O, Vu B, Tamanoi F, AlMalik A, Khashab NM. Impact of Pore-Walls Ligand Assembly on the Biodegradation of Mesoporous Organosilica Nanoparticles for Controlled Drug Delivery. ACS Omega. 2018 May 31; 3(5):5195-5201. PMID: 31458733.
      View in: PubMed
    10. Doura T, Tamanoi F, Nakamura M. Miniaturization of thiol-organosilica nanoparticles induced by an anionic surfactant. J Colloid Interface Sci. 2018 Sep 15; 526:51-62. PMID: 29715615.
      View in: PubMed
    11. Shahin SA, Wang R, Simargi SI, Contreras A, Parra Echavarria L, Qu L, Wen W, Dellinger T, Unternaehrer J, Tamanoi F, Zink JI, Glackin CA. Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine. 2018 06; 14(4):1381-1394. PMID: 29665439.
      View in: PubMed
    12. Faridi N, Bathaie SZ, Abroun S, Farzaneh P, Karbasian H, Tamanoi F, Mohagheghi MA. Isolation and characterization of the primary epithelial breast cancer cells and the adjacent normal epithelial cells from Iranian women's breast cancer tumors. Cytotechnology. 2018 Apr; 70(2):625-639. PMID: 29380298.
      View in: PubMed
    13. Heard JJ, Phung I, Potes MI, Tamanoi F. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. BMC Cancer. 2018 01 10; 18(1):69. PMID: 29320991.
      View in: PubMed
    14. Tamanoi F. Preface. Enzymes. 2018; 43:xi. PMID: 30244810.
      View in: PubMed
    15. Tamanoi F. Preface. Enzymes. 2018; 44:xi. PMID: 30360817.
      View in: PubMed
    16. Hayashi JY, Tamanoi F. Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy. Enzymes. 2017; 42:153-172. PMID: 29054269.
      View in: PubMed
    17. Tanaka A, Radwan MO, Hamasaki A, Ejima A, Obata E, Koga R, Tateishi H, Okamoto Y, Fujita M, Nakao M, Umezawa K, Tamanoi F, Otsuka M. A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group. Bioorg Med Chem Lett. 2017 08 15; 27(16):3862-3866. PMID: 28666734.
      View in: PubMed
    18. Hu TY, Tamanoi F. Preface. Enzymes. 2017; 42:xi. PMID: 29054273.
      View in: PubMed
    19. Bathaie SZ, Ashrafi M, Azizian M, Tamanoi F. Mevalonate Pathway and Human Cancers. Curr Mol Pharmacol. 2017; 10(2):77-85. PMID: 26758953.
      View in: PubMed
    20. Roberts CM, Shahin SA, Wen W, Finlay JB, Dong J, Wang R, Dellinger TH, Zink JI, Tamanoi F, Glackin CA. Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models. Nanomedicine. 2017 04; 13(3):965-976. PMID: 27890656.
      View in: PubMed
    21. Croissant JG, Fatieiev Y, Julfakyan K, Lu J, Emwas AH, Anjum DH, Omar H, Tamanoi F, Zink JI, Khashab NM. Biodegradable Oxamide-Phenylene-Based Mesoporous Organosilica Nanoparticles with Unprecedented Drug Payloads for Delivery in Cells. Chemistry. 2016 Oct 10; 22(42):14806-14811. PMID: 27258139.
      View in: PubMed
    22. Croissant JG, Fatieiev Y, Omar H, Anjum DH, Gurinov A, Lu J, Tamanoi F, Zink JI, Khashab NM. Periodic Mesoporous Organosilica Nanoparticles with Controlled Morphologies and High Drug/Dye Loadings for Multicargo Delivery in Cancer Cells. Chemistry. 2016 07 04; 22(28):9607-15. PMID: 27245497.
      View in: PubMed
    23. Croissant JG, Zhang D, Alsaiari S, Lu J, Deng L, Tamanoi F, AlMalik AM, Zink JI, Khashab NM. Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging. J Control Release. 2016 05 10; 229:183-191. PMID: 27016140.
      View in: PubMed
    24. Kaguni LS, Oliveira MT, Tamanoi F. Preface. Enzymes. 2016; 39:xi. PMID: 27241935.
      View in: PubMed
    25. Lin C, Luan S, Tamanoi F. Preface. Enzymes. 2016; 40:ix-x. PMID: 27776784.
      View in: PubMed
    26. Mekaru H, Lu J, Tamanoi F. Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy. Adv Drug Deliv Rev. 2015 Dec 01; 95:40-9. PMID: 26434537.
      View in: PubMed
    27. Lu J, Yoshimura K, Goto K, Lee C, Hamura K, Kwon O, Tamanoi F. Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells. PLoS One. 2015; 10(9):e0137595. PMID: 26352258.
      View in: PubMed
    28. Bathaie SZ, Faridi N, Nasimian A, Heidarzadeh H, Tamanoi F. How Phytochemicals Prevent Chemical Carcinogens and/or Suppress Tumor Growth? Enzymes. 2015; 37:1-42. PMID: 26298454.
      View in: PubMed
    29. Chantaravisoot N, Wongkongkathep P, Loo JA, Mischel PS, Tamanoi F. Significance of filamin A in mTORC2 function in glioblastoma. Mol Cancer. 2015 Jul 02; 14:127. PMID: 26134617.
      View in: PubMed
    30. Finlay J, Roberts CM, Dong J, Zink JI, Tamanoi F, Glackin CA. Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. Nanomedicine. 2015 Oct; 11(7):1657-66. PMID: 26115637.
      View in: PubMed
    31. Mortazavi F, Lu J, Phan R, Lewis M, Trinidad K, Aljilani A, Pezeshkpour G, Tamanoi F. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. BMC Cancer. 2015 May 09; 15:381. PMID: 25956913.
      View in: PubMed
    32. Bathaie SZ, Tamanoi F. Preface. Enzymes. 2015; 37:xiii. PMID: 26298462.
      View in: PubMed
    33. Inoue K, Stafforini D, Tamanoi F. Preface. Enzymes. 2015; 38:xi. PMID: 26612653.
      View in: PubMed
    34. Sato T, Akasu H, Shimono W, Matsu C, Fujiwara Y, Shibagaki Y, Heard JJ, Tamanoi F, Hattori S. Rheb protein binds CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase) protein in a GTP- and effector domain-dependent manner and influences its cellular localization and carbamoyl-phosphate synthetase (CPSase) activity. J Biol Chem. 2015 Jan 09; 290(2):1096-105. PMID: 25422319.
      View in: PubMed
    35. Hwang AA, Lu J, Tamanoi F, Zink JI. Functional nanovalves on protein-coated nanoparticles for in vitro and in vivo controlled drug delivery. Small. 2015 Jan 21; 11(3):319-328. PMID: 25196485.
      View in: PubMed
    36. Théron C, Gallud A, Carcel C, Gary-Bobo M, Maynadier M, Garcia M, Lu J, Tamanoi F, Zink JI, Wong Chi Man M. Hybrid mesoporous silica nanoparticles with pH-operated and complementary H-bonding caps as an autonomous drug-delivery system. Chemistry. 2014 Jul 21; 20(30):9372-80. PMID: 24986399.
      View in: PubMed
    37. Nakashima A, Kamada S, Tamanoi F, Kikkawa U. Fission yeast arrestin-related trafficking adaptor, Arn1/Any1, is ubiquitinated by Pub1 E3 ligase and regulates endocytosis of Cat1 amino acid transporter. Biol Open. 2014 May 29; 3(6):542-52. PMID: 24876389.
      View in: PubMed
    38. Heard JJ, Fong V, Bathaie SZ, Tamanoi F. Recent progress in the study of the Rheb family GTPases. Cell Signal. 2014 Sep; 26(9):1950-7. PMID: 24863881.
      View in: PubMed
    39. Tamanoi F. [Recent developments in targeted therapy for cancers and drug discovery]. Nihon Yakurigaku Zasshi. 2014 May; 143(5):236-42. PMID: 24813794.
      View in: PubMed
    40. Croissant J, Chaix A, Mongin O, Wang M, Clément S, Raehm L, Durand JO, Hugues V, Blanchard-Desce M, Maynadier M, Gallud A, Gary-Bobo M, Garcia M, Lu J, Tamanoi F, Ferris DP, Tarn D, Zink JI. Two-photon-triggered drug delivery via fluorescent nanovalves. Small. 2014 May 14; 10(9):1752-5. PMID: 24678053.
      View in: PubMed
    41. Coffman K, Yang B, Lu J, Tetlow AL, Pelliccio E, Lu S, Guo DC, Tang C, Dong MQ, Tamanoi F. Characterization of the Raptor/4E-BP1 interaction by chemical cross-linking coupled with mass spectrometry analysis. J Biol Chem. 2014 Feb 21; 289(8):4723-34. PMID: 24403073.
      View in: PubMed
    42. Machinda Y, Lin C, Tamanoi F. Preface. Enzymes. 2014; 35:xi-xiii. PMID: 25740722.
      View in: PubMed
    43. Bathaie SZ, Tamanoi F. Introduction. Enzymes. 2014; 36:1-6. PMID: 27102696.
      View in: PubMed
    44. Bathaie SZ, Bolhassani A, Tamanoi F. Anticancer Effect and Molecular Targets of Saffron Carotenoids. Enzymes. 2014; 36:57-86. PMID: 27102699.
      View in: PubMed
    45. Tamanoi F, Lu J. Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions. Enzymes. 2013; 34 Pt. B:181-200. PMID: 25034105.
      View in: PubMed
    46. Tamanoi F, Der CJ. Inhibitors of the Ras superfamily of small G-proteins. Preface. Enzymes. 2013; 34 Pt. B:ix. PMID: 25034107.
      View in: PubMed
    47. Croissant J, Maynadier M, Gallud A, Peindy N'dongo H, Nyalosaso JL, Derrien G, Charnay C, Durand JO, Raehm L, Serein-Spirau F, Cheminet N, Jarrosson T, Mongin O, Blanchard-Desce M, Gary-Bobo M, Garcia M, Lu J, Tamanoi F, Tarn D, Guardado-Alvarez TM, Zink JI. Two-photon-triggered drug delivery in cancer cells using nanoimpellers. Angew Chem Int Ed Engl. 2013 Dec 16; 52(51):13813-7. PMID: 24214916.
      View in: PubMed
    48. Tetlow AL, Tamanoi F. The Ras superfamily G-proteins. Enzymes. 2013; 33 Pt A:1-14. PMID: 25033798.
      View in: PubMed
    49. Khazak V, Eyrisch S, Kato J, Tamanoi F, Golemis EA. A two-hybrid approach to identify inhibitors of the RAS-RAF interaction. Enzymes. 2013; 33 Pt A:213-48. PMID: 25033807.
      View in: PubMed
    50. Tamanoi F. Preface. Enzymes. 2013; 33 Pt A:ix. PMID: 25033810.
      View in: PubMed
    51. Zimonjic DB, Chan LN, Tripathi V, Lu J, Kwon O, Popescu NC, Lowy DR, Tamanoi F. In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells. BMC Cancer. 2013 Apr 22; 13:198. PMID: 23607551.
      View in: PubMed
    52. Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, Sasayama T, James CD, Kornblum HI, Cloughesy TF, Cavenee WK, Bensinger SJ, Mischel PS. De-repression of PDGFRß transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov. 2013 May; 3(5):534-47. PMID: 23533263.
      View in: PubMed
    53. Yanes RE, Tarn D, Hwang AA, Ferris DP, Sherman SP, Thomas CR, Lu J, Pyle AD, Zink JI, Tamanoi F. Involvement of lysosomal exocytosis in the excretion of mesoporous silica nanoparticles and enhancement of the drug delivery effect by exocytosis inhibition. Small. 2013 Mar 11; 9(5):697-704. PMID: 23152124.
      View in: PubMed
    54. Chanfreau G, Tamanoi F. Preface. Enzymes. 2012; 31:x-xii. PMID: 27166448.
      View in: PubMed
    55. Nakashima A, Otsubo Y, Yamashita A, Sato T, Yamamoto M, Tamanoi F. Psk1, an AGC kinase family member in fission yeast, is directly phosphorylated and controlled by TORC1 and functions as S6 kinase. J Cell Sci. 2012 Dec 01; 125(Pt 23):5840-9. PMID: 22976295.
      View in: PubMed
    56. Rettig M, Trinidad K, Pezeshkpour G, Frost P, Sharma S, Moatamed F, Tamanoi F, Mortazavi F. PAK1 kinase promotes cell motility and invasiveness through CRK-II serine phosphorylation in non-small cell lung cancer cells. PLoS One. 2012; 7(7):e42012. PMID: 22848689.
      View in: PubMed
    57. Hon NK, Shaposhnik Z, Diebold ED, Tamanoi F, Jalali B. Tailoring the biodegradability of porous silicon nanoparticles. J Biomed Mater Res A. 2012 Dec; 100(12):3416-21. PMID: 22767395.
      View in: PubMed
    58. Lau YA, Henderson BL, Lu J, Ferris DP, Tamanoi F, Zink JI. Continuous spectroscopic measurements of photo-stimulated release of molecules by nanomachines in a single living cell. Nanoscale. 2012 Jun 07; 4(11):3482-9. PMID: 22552632.
      View in: PubMed
    59. Yanes RE, Tamanoi F. Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery. Ther Deliv. 2012 Mar; 3(3):389-404. PMID: 22506096.
      View in: PubMed
    60. Chan LN, Fiji HD, Watanabe M, Kwon O, Tamanoi F. Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I. PLoS One. 2011; 6(10):e26135. PMID: 22028818.
      View in: PubMed
    61. Lu J, Li Z, Zink JI, Tamanoi F. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine. 2012 Feb; 8(2):212-20. PMID: 21703996.
      View in: PubMed
    62. Xue M, Zhong X, Shaposhnik Z, Qu Y, Tamanoi F, Duan X, Zink JI. pH-Operated mechanized porous silicon nanoparticles. J Am Chem Soc. 2011 Jun 15; 133(23):8798-801. PMID: 21595466.
      View in: PubMed
    63. Ferris DP, Lu J, Gothard C, Yanes R, Thomas CR, Olsen JC, Stoddart JF, Tamanoi F, Zink JI. Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Small. 2011 Jul 04; 7(13):1816-26. PMID: 21595023.
      View in: PubMed
    64. Tamanoi F. Ras signaling in yeast. Genes Cancer. 2011 Mar; 2(3):210-5. PMID: 21779494.
      View in: PubMed
    65. Hardt M, Chantaravisoot N, Tamanoi F. Activating mutations of TOR (target of rapamycin). Genes Cells. 2011 Feb; 16(2):141-51. PMID: 21210909.
      View in: PubMed
    66. Meng H, Xue M, Xia T, Zhao YL, Tamanoi F, Stoddart JF, Zink JI, Nel AE. Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. J Am Chem Soc. 2010 Sep 15; 132(36):12690-7. PMID: 20718462.
      View in: PubMed
    67. Lu J, Liong M, Li Z, Zink JI, Tamanoi F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small. 2010 Aug 16; 6(16):1794-805. PMID: 20623530.
      View in: PubMed
    68. Hom C, Lu J, Liong M, Luo H, Li Z, Zink JI, Tamanoi F. Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Small. 2010 Jun 06; 6(11):1185-90. PMID: 20461725.
      View in: PubMed
    69. Jiang H, Song C, Chen CC, Xu R, Raines KS, Fahimian BP, Lu CH, Lee TK, Nakashima A, Urano J, Ishikawa T, Tamanoi F, Miao J. Quantitative 3D imaging of whole, unstained cells by using X-ray diffraction microscopy. Proc Natl Acad Sci U S A. 2010 Jun 22; 107(25):11234-9. PMID: 20534442.
      View in: PubMed
    70. Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene. 2010 May 06; 29(18):2746-52. PMID: 20190810.
      View in: PubMed
    71. Nakashima A, Sato T, Tamanoi F. Fission yeast TORC1 regulates phosphorylation of ribosomal S6 proteins in response to nutrients and its activity is inhibited by rapamycin. J Cell Sci. 2010 Mar 01; 123(Pt 5):777-86. PMID: 20144990.
      View in: PubMed
    72. Sato T, Nakashima A, Tamanoi F. [Rheb-mTOR signaling pathway involved in tumor formation]. Tanpakushitsu Kakusan Koso. 2010 Jan; 55(1):11-7. PMID: 20058701.
      View in: PubMed
    73. Nakashima A, Tamanoi F. Conservation of the Tsc/Rheb/TORC1/S6K/S6 Signaling in Fission Yeast. Enzymes. 2010; 28:167-187. PMID: 25814783.
      View in: PubMed
    74. Parmar N, Tamanoi F. Rheb G-Proteins and the Activation of mTORC1. Enzymes. 2010; 27:39-56. PMID: 25429186.
      View in: PubMed
    75. Hanker AB, Mitin N, Wilder RS, Henske EP, Tamanoi F, Cox AD, Der CJ. Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling. Oncogene. 2010 Jan 21; 29(3):380-91. PMID: 19838215.
      View in: PubMed
    76. Chan LN, Hart C, Guo L, Nyberg T, Davies BS, Fong LG, Young SG, Agnew BJ, Tamanoi F. A novel approach to tag and identify geranylgeranylated proteins. Electrophoresis. 2009 Oct; 30(20):3598-606. PMID: 19784953.
      View in: PubMed
    77. Lu J, Chan L, Fiji HD, Dahl R, Kwon O, Tamanoi F. In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Mol Cancer Ther. 2009 May; 8(5):1218-26. PMID: 19417142.
      View in: PubMed
    78. Sato T, Nakashima A, Guo L, Tamanoi F. Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. J Biol Chem. 2009 May 08; 284(19):12783-91. PMID: 19299511.
      View in: PubMed
    79. Zhou J, Vos CC, Gjyrezi A, Yoshida M, Khuri FR, Tamanoi F, Giannakakou P. The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner. J Biol Chem. 2009 Apr 10; 284(15):9648-55. PMID: 19228685.
      View in: PubMed
    80. Klichko Y, Liong M, Choi E, Angelos S, Nel AE, Stoddart JF, Tamanoi F, Zink JI. Mesostructured Silica for Optical Functionality, Nanomachines, and Drug Delivery. J Am Ceram Soc. 2009 Jan 01; 92(s1):s2-s10. PMID: 19834571.
      View in: PubMed
    81. Hom C, Lu J, Tamanoi F. Silica nanoparticles as a delivery system for nucleic acid-based reagents. J Mater Chem. 2009 Jan 01; 19(35):6308-6316. PMID: 20740060.
      View in: PubMed
    82. Davies BS, Yang SH, Farber E, Lee R, Buck SB, Andres DA, Spielmann HP, Agnew BJ, Tamanoi F, Fong LG, Young SG. Increasing the length of progerin's isoprenyl anchor does not worsen bone disease or survival in mice with Hutchinson-Gilford progeria syndrome. J Lipid Res. 2009 Jan; 50(1):126-34. PMID: 18757838.
      View in: PubMed
    83. Short JD, Houston KD, Dere R, Cai SL, Kim J, Johnson CL, Broaddus RR, Shen J, Miyamoto S, Tamanoi F, Kwiatkowski D, Mills GB, Walker CL. AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. Cancer Res. 2008 Aug 15; 68(16):6496-506. PMID: 18701472.
      View in: PubMed
    84. Liong M, Lu J, Kovochich M, Xia T, Ruehm SG, Nel AE, Tamanoi F, Zink JI. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano. 2008 May; 2(5):889-96. PMID: 19206485.
      View in: PubMed
    85. Aspuria PJ, Tamanoi F. The Tsc/Rheb signaling pathway controls basic amino acid uptake via the Cat1 permease in fission yeast. Mol Genet Genomics. 2008 May; 279(5):441-50. PMID: 18219492.
      View in: PubMed
    86. Lu J, Choi E, Tamanoi F, Zink JI. Light-activated nanoimpeller-controlled drug release in cancer cells. Small. 2008 Apr; 4(4):421-6. PMID: 18383576.
      View in: PubMed
    87. Watanabe M, Fiji HD, Guo L, Chan L, Kinderman SS, Slamon DJ, Kwon O, Tamanoi F. Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. J Biol Chem. 2008 Apr 11; 283(15):9571-9. PMID: 18230616.
      View in: PubMed
    88. Sato T, Umetsu A, Tamanoi F. Characterization of the Rheb-mTOR signaling pathway in mammalian cells: constitutive active mutants of Rheb and mTOR. Methods Enzymol. 2008; 438:307-20. PMID: 18413257.
      View in: PubMed
    89. Ikeda K, Morigasaki S, Tatebe H, Tamanoi F, Shiozaki K. Fission yeast TOR complex 2 activates the AGC-family Gad8 kinase essential for stress resistance and cell cycle control. Cell Cycle. 2008 Feb 01; 7(3):358-64. PMID: 18235227.
      View in: PubMed
    90. Lu J, Liong M, Zink JI, Tamanoi F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small. 2007 Aug; 3(8):1341-6. PMID: 17566138.
      View in: PubMed
    91. Aspuria PJ, Sato T, Tamanoi F. The TSC/Rheb/TOR signaling pathway in fission yeast and mammalian cells: temperature sensitive and constitutive active mutants of TOR. Cell Cycle. 2007 Jul 15; 6(14):1692-5. PMID: 17637564.
      View in: PubMed
    92. Lu J, Liong M, Sherman S, Xia T, Kovochich M, Nel AE, Zink JI, Tamanoi F. Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells. Nanobiotechnology. 2007 May 01; 3(2):89-95. PMID: 19936038.
      View in: PubMed
    93. Castellano S, Fiji HD, Kinderman SS, Watanabe M, Leon Pd, Tamanoi F, Kwon O. Small-molecule inhibitors of protein geranylgeranyltransferase type I. J Am Chem Soc. 2007 May 09; 129(18):5843-5. PMID: 17439124.
      View in: PubMed
    94. Yu F, Harada JN, Brown HJ, Deng H, Song MJ, Wu TT, Kato-Stankiewicz J, Nelson CG, Vieira J, Tamanoi F, Chanda SK, Sun R. Systematic identification of cellular signals reactivating Kaposi sarcoma-associated herpesvirus. PLoS Pathog. 2007 Mar; 3(3):e44. PMID: 17397260.
      View in: PubMed
    95. Urano J, Sato T, Matsuo T, Otsubo Y, Yamamoto M, Tamanoi F. Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. Proc Natl Acad Sci U S A. 2007 Feb 27; 104(9):3514-9. PMID: 17360675.
      View in: PubMed
    96. Matsuo T, Otsubo Y, Urano J, Tamanoi F, Yamamoto M. Loss of the TOR kinase Tor2 mimics nitrogen starvation and activates the sexual development pathway in fission yeast. Mol Cell Biol. 2007 Apr; 27(8):3154-64. PMID: 17261596.
      View in: PubMed
    97. Patel PH, Tamanoi F. Increased Rheb-TOR signaling enhances sensitivity of the whole organism to oxidative stress. J Cell Sci. 2006 Oct 15; 119(Pt 20):4285-92. PMID: 17038544.
      View in: PubMed
    98. Gelb MH, Brunsveld L, Hrycyna CA, Michaelis S, Tamanoi F, Van Voorhis WC, Waldmann H. Therapeutic intervention based on protein prenylation and associated modifications. Nat Chem Biol. 2006 Oct; 2(10):518-28. PMID: 16983387.
      View in: PubMed
    99. Ikeda A, Shankar DB, Watanabe M, Tamanoi F, Moore TB, Sakamoto KM. Molecular targets and the treatment of myeloid leukemia. Mol Genet Metab. 2006 Jul; 88(3):216-24. PMID: 16678459.
      View in: PubMed
    100. Patel PH, Tamanoi F. Using Drosophila and yeast genetics to investigate a role for the Rheb GTPase in cell growth. Methods Enzymol. 2006; 407:443-54. PMID: 16757344.
      View in: PubMed
    101. Khazak V, Kato-Stankiewicz J, Tamanoi F, Golemis EA. Yeast screens for inhibitors of Ras-Raf interaction and characterization of MCP inhibitors of Ras-Raf interaction. Methods Enzymol. 2006; 407:612-29. PMID: 16757356.
      View in: PubMed
    102. Urano J, Comiso MJ, Guo L, Aspuria PJ, Deniskin R, Tabancay AP, Kato-Stankiewicz J, Tamanoi F. Identification of novel single amino acid changes that result in hyperactivation of the unique GTPase, Rheb, in fission yeast. Mol Microbiol. 2005 Nov; 58(4):1074-86. PMID: 16262791.
      View in: PubMed
    103. Gau CL, Kato-Stankiewicz J, Jiang C, Miyamoto S, Guo L, Tamanoi F. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways. Mol Cancer Ther. 2005 Jun; 4(6):918-26. PMID: 15956249.
      View in: PubMed
    104. Aspuria PJ, Tamanoi F. The Rheb family of GTP-binding proteins. Cell Signal. 2004 Oct; 16(10):1105-12. PMID: 15240005.
      View in: PubMed
    105. Kho Y, Kim SC, Jiang C, Barma D, Kwon SW, Cheng J, Jaunbergs J, Weinbaum C, Tamanoi F, Falck J, Zhao Y. A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. Proc Natl Acad Sci U S A. 2004 Aug 24; 101(34):12479-84. PMID: 15308774.
      View in: PubMed
    106. Uhlmann EJ, Li W, Scheidenhelm DK, Gau CL, Tamanoi F, Gutmann DH. Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. Glia. 2004 Aug 01; 47(2):180-8. PMID: 15185396.
      View in: PubMed
    107. Clarke S, Tamanoi F. Fighting cancer by disrupting C-terminal methylation of signaling proteins. J Clin Invest. 2004 Feb; 113(4):513-5. PMID: 14966560.
      View in: PubMed
    108. Patel PH, Thapar N, Guo L, Martinez M, Maris J, Gau CL, Lengyel JA, Tamanoi F. Drosophila Rheb GTPase is required for cell cycle progression and cell growth. J Cell Sci. 2003 Sep 01; 116(Pt 17):3601-10. PMID: 12893813.
      View in: PubMed
    109. Tabancay AP, Gau CL, Machado IM, Uhlmann EJ, Gutmann DH, Guo L, Tamanoi F. Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. J Biol Chem. 2003 Oct 10; 278(41):39921-30. PMID: 12869548.
      View in: PubMed
    110. Hamasaki A, Naka H, Tamanoi F, Umezawa K, Otsuka M. A novel metal-chelating inhibitor of protein farnesyltransferase. Bioorg Med Chem Lett. 2003 May 05; 13(9):1523-6. PMID: 12699746.
      View in: PubMed
    111. Kato-Stankiewicz J, Hakimi I, Zhi G, Zhang J, Serebriiskii I, Guo L, Edamatsu H, Koide H, Menon S, Eckl R, Sakamuri S, Lu Y, Chen QZ, Agarwal S, Baumbach WR, Golemis EA, Tamanoi F, Khazak V. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc Natl Acad Sci U S A. 2002 Oct 29; 99(22):14398-403. PMID: 12391290.
      View in: PubMed
    112. Tamanoi F, Gau CL, Jiang C, Edamatsu H, Kato-Stankiewicz J. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell Mol Life Sci. 2001 Oct; 58(11):1636-49. PMID: 11706990.
      View in: PubMed
    113. Yang W, Tabancay AP, Urano J, Tamanoi F. Failure to farnesylate Rheb protein contributes to the enrichment of G0/G1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant. Mol Microbiol. 2001 Sep; 41(6):1339-47. PMID: 11580838.
      View in: PubMed
    114. Finlin BS, Gau CL, Murphy GA, Shao H, Kimel T, Seitz RS, Chiu YF, Botstein D, Brown PO, Der CJ, Tamanoi F, Andres DA, Perou CM. RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer. J Biol Chem. 2001 Nov 09; 276(45):42259-67. PMID: 11533059.
      View in: PubMed
    115. Pervin S, Singh R, Gau CL, Edamatsu H, Tamanoi F, Chaudhuri G. Potentiation of nitric oxide-induced apoptosis of MDA-MB-468 cells by farnesyltransferase inhibitor: implications in breast cancer. Cancer Res. 2001 Jun 15; 61(12):4701-6. PMID: 11406540.
      View in: PubMed
    116. Urano J, Ellis C, Clark GJ, Tamanoi F. Characterization of Rheb functions using yeast and mammalian systems. Methods Enzymol. 2001; 333:217-31. PMID: 11400338.
      View in: PubMed
    117. Tamanoi F, Kato-Stankiewicz J, Jiang C, Machado I, Thapar N. Farnesylated proteins and cell cycle progression. J Cell Biochem Suppl. 2001; Suppl 37:64-70. PMID: 11842430.
      View in: PubMed
    118. Edamatsu H, Gau CL, Nemoto T, Guo L, Tamanoi F. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene. 2000 Jun 22; 19(27):3059-68. PMID: 10871858.
      View in: PubMed
    119. Urano J, Tabancay AP, Yang W, Tamanoi F. The Saccharomyces cerevisiae Rheb G-protein is involved in regulating canavanine resistance and arginine uptake. J Biol Chem. 2000 Apr 14; 275(15):11198-206. PMID: 10753927.
      View in: PubMed
    120. Yang W, Urano J, Tamanoi F. Protein farnesylation is critical for maintaining normal cell morphology and canavanine resistance in Schizosaccharomyces pombe. J Biol Chem. 2000 Jan 07; 275(1):429-38. PMID: 10617635.
      View in: PubMed
    121. Del Villar K, Urano J, Guo L, Tamanoi F. A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors. J Biol Chem. 1999 Sep 17; 274(38):27010-7. PMID: 10480914.
      View in: PubMed
    122. Robinson NG, Guo L, Imai J, Toh-E A, Matsui Y, Tamanoi F. Rho3 of Saccharomyces cerevisiae, which regulates the actin cytoskeleton and exocytosis, is a GTPase which interacts with Myo2 and Exo70. Mol Cell Biol. 1999 May; 19(5):3580-7. PMID: 10207081.
      View in: PubMed
    123. Urano J, Tamanoi F. Reconstitution of yeast farnesyltransferase from individually purified subunits. Methods Mol Biol. 1999; 116:145-59. PMID: 10399151.
      View in: PubMed
    124. Suzuki N, Urano J, Tamanoi F. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc Natl Acad Sci U S A. 1998 Dec 22; 95(26):15356-61. PMID: 9860973.
      View in: PubMed
    125. Suzuki N, Del Villar K, Tamanoi F. Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents. Proc Natl Acad Sci U S A. 1998 Sep 01; 95(18):10499-504. PMID: 9724732.
      View in: PubMed
    126. Arellano M, Coll PM, Yang W, Duran A, Tamanoi F, Perez P. Characterization of the geranylgeranyl transferase type I from Schizosaccharomyces pombe. Mol Microbiol. 1998 Sep; 29(6):1357-67. PMID: 9781874.
      View in: PubMed
    127. Scoles DR, Huynh DP, Morcos PA, Coulsell ER, Robinson NG, Tamanoi F, Pulst SM. Neurofibromatosis 2 tumour suppressor schwannomin interacts with betaII-spectrin. Nat Genet. 1998 Apr; 18(4):354-9. PMID: 9537418.
      View in: PubMed
    128. Del Villar K, Mitsuzawa H, Yang W, Sattler I, Tamanoi F. Amino acid substitutions that convert the protein substrate specificity of farnesyltransferase to that of geranylgeranyltransferase type I. J Biol Chem. 1997 Jan 03; 272(1):680-7. PMID: 8995312.
      View in: PubMed
    129. Yang W, Del Villar K, Urano J, Mitsuzawa H, Tamanoi F. Advances in the development of farnesyltransferase inhibitors: substrate recognition by protein farnesyltransferase. J Cell Biochem Suppl. 1997; 27:12-9. PMID: 9591188.
      View in: PubMed
    130. Del Villar K, Dorin D, Sattler I, Urano J, Poullet P, Robinson N, Mitsuzawa H, Tamanoi F. C-terminal motifs found in Ras-superfamily G-proteins: CAAX and C-seven motifs. Biochem Soc Trans. 1996 Aug; 24(3):709-13. PMID: 8878831.
      View in: PubMed
    131. Morcos P, Thapar N, Tusneem N, Stacey D, Tamanoi F. Identification of neurofibromin mutants that exhibit allele specificity or increased Ras affinity resulting in suppression of activated ras alleles. Mol Cell Biol. 1996 May; 16(5):2496-503. PMID: 8628317.
      View in: PubMed
    132. Dorin D, Cohen L, Del Villar K, Poullet P, Mohr R, Whiteway M, Witte O, Tamanoi F. Kir, a novel Ras-family G-protein, induces invasive pseudohyphal growth in Saccharomyces cerevisiae. Oncogene. 1995 Dec 07; 11(11):2267-71. PMID: 8570176.
      View in: PubMed
    133. Baba H, Fuss B, Urano J, Poullet P, Watson JB, Tamanoi F, Macklin WB. GapIII, a new brain-enriched member of the GTPase-activating protein family. J Neurosci Res. 1995 Aug 15; 41(6):846-58. PMID: 7500386.
      View in: PubMed
    134. Gelb MH, Tamanoi F, Yokoyama K, Ghomashchi F, Esson K, Gould MN. The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol. Cancer Lett. 1995 May 08; 91(2):169-75. PMID: 7767906.
      View in: PubMed
    135. Mitsuzawa H, Esson K, Tamanoi F. Mutant farnesyltransferase beta subunit of Saccharomyces cerevisiae that can substitute for geranylgeranyltransferase type I beta subunit. Proc Natl Acad Sci U S A. 1995 Feb 28; 92(5):1704-8. PMID: 7878044.
      View in: PubMed
    136. Poullet P, Tamanoi F. Use of yeast two-hybrid system to evaluate Ras interactions with neurofibromin-GTPase-activating protein. Methods Enzymol. 1995; 255:488-97. PMID: 8524136.
      View in: PubMed
    137. Tamanoi F, Mitsuzawa H. Use of yeast for identification of farnesyltransferase inhibitors and for generation of mutant farnesyltransferases. Methods Enzymol. 1995; 255:82-91. PMID: 8524140.
      View in: PubMed
    138. Mitsuzawa H, Tamanoi F. In vivo assays for farnesyltransferase inhibitors with Saccharomyces cerevisiae. Methods Enzymol. 1995; 250:43-51. PMID: 7651169.
      View in: PubMed
    139. Cohen L, Mohr R, Chen YY, Huang M, Kato R, Dorin D, Tamanoi F, Goga A, Afar D, Rosenberg N. Transcriptional activation of a ras-like gene (kir) by oncogenic tyrosine kinases. Proc Natl Acad Sci U S A. 1994 Dec 20; 91(26):12448-52. PMID: 7809057.
      View in: PubMed
    140. Wood DR, Poullet P, Wilson BA, Khalil M, Tanaka K, Cannon JF, Tamanoi F. Biochemical characterization of yeast RAS2 mutants reveals a new region of ras protein involved in the interaction with GTPase-activating proteins. J Biol Chem. 1994 Feb 18; 269(7):5322-7. PMID: 8106517.
      View in: PubMed
    141. Poullet P, Lin B, Esson K, Tamanoi F. Functional significance of lysine 1423 of neurofibromin and characterization of a second site suppressor which rescues mutations at this residue and suppresses RAS2Val-19-activated phenotypes. Mol Cell Biol. 1994 Jan; 14(1):815-21. PMID: 8264648.
      View in: PubMed
    142. Díaz M, Sanchez Y, Bennett T, Sun CR, Godoy C, Tamanoi F, Duran A, Perez P. The Schizosaccharomyces pombe cwg2+ gene codes for the beta subunit of a geranylgeranyltransferase type I required for beta-glucan synthesis. EMBO J. 1993 Dec 15; 12(13):5245-54. PMID: 8262067.
      View in: PubMed
    143. Wilson BA, Khalil M, Tamanoi F, Cannon JF. New activated RAS2 mutations identified in Saccharomyces cerevisiae. Oncogene. 1993 Dec; 8(12):3441-5. PMID: 8247549.
      View in: PubMed
    144. Tamanoi F. Inhibitors of Ras farnesyltransferases. Trends Biochem Sci. 1993 Sep; 18(9):349-53. PMID: 8236454.
      View in: PubMed
    145. Hara M, Akasaka K, Akinaga S, Okabe M, Nakano H, Gomez R, Wood D, Uh M, Tamanoi F. Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci U S A. 1993 Mar 15; 90(6):2281-5. PMID: 8460134.
      View in: PubMed
    146. Gomez R, Goodman LE, Tripathy SK, O'Rourke E, Manne V, Tamanoi F. Purified yeast protein farnesyltransferase is structurally and functionally similar to its mammalian counterpart. Biochem J. 1993 Jan 01; 289 ( Pt 1):25-31. PMID: 8424764.
      View in: PubMed
    147. Tanaka K, Wood DR, Lin BK, Khalil M, Tamanoi F, Cannon JF. A dominant activating mutation in the effector region of RAS abolishes IRA2 sensitivity. Mol Cell Biol. 1992 Feb; 12(2):631-7. PMID: 1732735.
      View in: PubMed
    148. Golubic M, Tanaka K, Dobrowolski S, Wood D, Tsai MH, Marshall M, Tamanoi F, Stacey DW. The GTPase stimulatory activities of the neurofibromatosis type 1 and the yeast IRA2 proteins are inhibited by arachidonic acid. EMBO J. 1991 Oct; 10(10):2897-903. PMID: 1915269.
      View in: PubMed
    149. Finegold AA, Johnson DI, Farnsworth CC, Gelb MH, Judd SR, Glomset JA, Tamanoi F. Protein geranylgeranyltransferase of Saccharomyces cerevisiae is specific for Cys-Xaa-Xaa-Leu motif proteins and requires the CDC43 gene product but not the DPR1 gene product. Proc Natl Acad Sci U S A. 1991 May 15; 88(10):4448-52. PMID: 2034682.
      View in: PubMed
    150. Tanaka K, Lin BK, Wood DR, Tamanoi F. IRA2, an upstream negative regulator of RAS in yeast, is a RAS GTPase-activating protein. Proc Natl Acad Sci U S A. 1991 Jan 15; 88(2):468-72. PMID: 1988946.
      View in: PubMed
    151. Goodman LE, Judd SR, Farnsworth CC, Powers S, Gelb MH, Glomset JA, Tamanoi F. Mutants of Saccharomyces cerevisiae defective in the farnesylation of Ras proteins. Proc Natl Acad Sci U S A. 1990 Dec; 87(24):9665-9. PMID: 2124698.
      View in: PubMed
    152. Xu GF, Lin B, Tanaka K, Dunn D, Wood D, Gesteland R, White R, Weiss R, Tamanoi F. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell. 1990 Nov 16; 63(4):835-41. PMID: 2121369.
      View in: PubMed
    153. Tanaka K, Nakafuku M, Tamanoi F, Kaziro Y, Matsumoto K, Toh-e A. IRA2, a second gene of Saccharomyces cerevisiae that encodes a protein with a domain homologous to mammalian ras GTPase-activating protein. Mol Cell Biol. 1990 Aug; 10(8):4303-13. PMID: 2164637.
      View in: PubMed
    154. Finegold AA, Schafer WR, Rine J, Whiteway M, Tamanoi F. Common modifications of trimeric G proteins and ras protein: involvement of polyisoprenylation. Science. 1990 Jul 13; 249(4965):165-9. PMID: 1695391.
      View in: PubMed
    155. Fujiyama A, Matsumoto K, Tamanoi F. A novel yeast mutant defective in the processing of ras proteins: assessment of the effect of the mutation on processing steps. EMBO J. 1987 Jan; 6(1):223-8. PMID: 3556161.
      View in: PubMed
    156. Hughes S, Mellstrom K, Kosik E, Tamanoi F, Brugge J. Mutation of a termination codon affects src initiation. Mol Cell Biol. 1984 Sep; 4(9):1738-46. PMID: 6092936.
      View in: PubMed